Evidence map›Paper›PMID 37242796›Full record

ArticlePharmaceutics2023

Development of Lyophilised Eudragit

Rosamaria Lombardo, Marika Ruponen, Jarkko Rautio, Carla Ghelardini, Lorenzo Di Cesare Mannelli, Laura Calosi, Daniele Bani, Riikka Lampinen, Katja M Kanninen, Anne M Koivisto and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rosamaria LombardoLaboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0009-0005-8227-915X
Marika RuponenSchool of Pharmacy, University of Eastern Finland, Yliopistonranta 1C, 70210 Kuopio, Finland.
Jarkko RautioSchool of Pharmacy, University of Eastern Finland, Yliopistonranta 1C, 70210 Kuopio, Finland.ORCID 0000-0003-2172-3980
Carla GhelardiniDepartment of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA)-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.
Lorenzo Di Cesare MannelliDepartment of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA)-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.ORCID 0000-0001-8374-4432
Laura CalosiPlatform of Imaging, Department of Experimental & Clinical Medicine, University of Florence, 50139 Florence, Italy.
Daniele BaniPlatform of Imaging, Department of Experimental & Clinical Medicine, University of Florence, 50139 Florence, Italy.ORCID 0000-0001-6302-901X
Riikka LampinenA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland.ORCID 0000-0002-1485-5179
Katja M KanninenA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland.ORCID 0000-0002-6717-8589
Anne M KoivistoBrain Research Unit, Department of Neurology, School of Medicine, University of Eastern Finland, 70200 Kuopio, Finland.
Elina PenttiläDepartment of Otorhinolaryngology, University of Eastern Finland, Kuopio University Hospital, 70210 Kuopio, Finland.
Heikki LöppönenDepartment of Otorhinolaryngology, University of Eastern Finland, Kuopio University Hospital, 70210 Kuopio, Finland.ORCID 0000-0002-2002-5358
Rosario PignatelloLaboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0000-0002-5937-4192

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clozapine (CZP) is the only effective drug in schizophrenia resistant to typical antipsychotics. However, existing dosage forms (oral or orodispersible tablets, suspensions or intramuscular injection) show challenging limitations. After oral administration, CZP has low bioavailability due to a large first-pass effect, while the i.m. route is often painful, with low patient compliance and requiring specialised personnel. Moreover, CZP has a very low aqueous solubility. This study proposes the intranasal route as an alternative route of administration for CZP, through its encapsulation in polymeric nanoparticles (NPs) based on Eudragit

Indexed as

cryoprotectantsEudragit RL100Eudragit RS100mucoadhesionnanomedicinestability

Identifiers

PMID37242796
PMCPMC10224374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.